Nodakenin ameliorates TNBS-induced experimental colitis in mice by inhibiting pyroptosis of intestinal epithelial cells.
10.12122/j.issn.1673-4254.2025.02.07
- Author:
Ju HUANG
1
;
Lixia YIN
2
;
Minzhu NIU
3
;
Zhijun GENG
1
;
Lugen ZUO
4
;
Jing LI
4
;
Jianguo HU
4
Author Information
1. Central Laboratory, First Affiliated Hospital of Bengbu Medical University, Bengbu 233003, China.
2. Department of Clinical Laboratory, First Affiliated Hospital of Bengbu Medical University, Bengbu 233003, China.
3. Department of Immunology, School of Laboratory Medicine, Bengbu Medical University, Bengbu 233000, China.
4. Anhui Provincial Key Laboratory of Basic and Translational Research of Inflammation-related Diseases, First Affiliated Hospital of Bengbu Medical University, Bengbu 233003, China.
- Publication Type:Journal Article
- Keywords:
Crohn's disease;
PI3K/Akt;
intestinal epithelial cell;
nodakenin;
pyroptosis
- MeSH:
Animals;
Pyroptosis/drug effects*;
Mice;
Trinitrobenzenesulfonic Acid;
Colitis/drug therapy*;
Epithelial Cells/drug effects*;
Intestinal Mucosa/cytology*;
Disease Models, Animal;
Coumarins/pharmacology*;
NLR Family, Pyrin Domain-Containing 3 Protein/metabolism*;
Crohn Disease/drug therapy*
- From:
Journal of Southern Medical University
2025;45(2):261-268
- CountryChina
- Language:Chinese
-
Abstract:
OBJECTIVES:To investigate the therapeutic mechanism of nodakenin for Crohn's disease (CD)-like colitis in mice.
METHODS:Using a colonic organoid model with lipopolysaccharide (LPS)- and ATP-induced pyroptosis, we investigated the effects of nodakenin on pyroptosis, intestinal barrier function and inflammatory response by detecting key pyroptosis-regulating factors and assessing changes in permeability and pro-inflammatory factors. In a mouse model of 2,4,6-trinitrobenzenesulfonic acid (TNBS)-induced CD-like colitis, the therapeutic effect of nodakenin was evaluated by measuring changes in body weight, DAI score, colonic histopathologies, inflammation score, intestinal barrier function and intestinal epithelial cell pyroptosis. The mechanism of nodakenin protection against pyroptosis of intestinal epithelial cells was explored using network pharmacology analysis and in vivo and in vitro experiments.
RESULTS:In LPS- and ATP-induced colonic organoids, treatment with nodakenin significantly inhibited the expressions of NLRP3, GSDMD-N, cleaved caspase-1 and caspase-11, improved intestinal FITC-dextran (FD4, 4000) permeability, and decreased the levels of IL-1β and IL-18. In the mouse model of TNBS-induced colitis, nodakenin treatment significantly alleviated weight loss, reduced DAI score, inflammatory cell infiltration and inflammation score, and decreased serum FD4 and I-FABP levels and bacteria translocation to the mesenteric lymph nodes, spleen and liver. The mice with nodakenin treatment had also lowered expressions of NLRP3, GSDMD-N, cleaved caspase-1 and caspase-11 in the intestinal mucosa. Network pharmacology analysis suggested that the inhibitory effect of nodakenin on colitis was associated with the PI3K/Akt pathway. In both the colonic organoid model and mouse models of colitis, nodakenin effectively inhibited the activation of the PI3K/Akt pathway, and the application of IGF-1, a PI3K/Akt pathway activator, strongly attenuated the protective effect of nodakenin against intestinal epithelial cell pyroptosis and intestinal barrier dysfunction.
CONCLUSIONS:Nodakenin protects intestinal barrier function and alleviates CD-like colitis in mice at least partly by inhibiting PI3K/Akt signaling to reduce intestinal epithelial cell pyroptosis.
